Surgical Treatment of Tricuspid Valve Regurgitation in Patients With

Status Completed

Clinical Trial Summary

Old trials aimed to evaluate Implantable Cardioverter-Defibrillator (ICD) safety and efficacy demonstrated a meaningful decreased rates of sudden death but an increased rate of hospitalization for heart failure . At the time, the chance that an endocardial lead could cause a significant tricuspid regurgitation (TR), leading to worsening heart failure, was not widely considered. Whereas, it is now well established that in patients with cardiac implantable electronic device (CIEDs), moderate or severe TR occurs frequently and it is associated with increased mortality and hospitalization for heart failure. The present study aims to report the long-term results of tricuspid valve repair and replacement surgery in patients with CIEDs Indeed, patients with TR and CIEDs can be divided in 2 categories: CIEDs induced TR and CIEDs associated TR. In patients with CIEDs induced TR, the valve dysfunction is directly caused by the lead with several mechanism such as mechanical interference with tricuspid valve (TV) leaflet mobility and coaptation (impingement), valve damage during lead placement or manipulation and sub-valvular entanglement. In patients with CIEDs associated TR the valve dysfunction is not directly caused by the lead. In 2009 approximately 720 000 CIEDs were implanted worldwide [7] and since then a continuous increase of CIEDs implantation was registered, with an estimation of 1.4 millions of CIEDs implantation in 2023. With this impressive number of CIEDs requirement, the need for surgical or trans-catheter treatment of severe TR CIEDs induced or associated, increased steadily in the past years and it likely will continue to increase in the next years. However, limited data are available regarding the outcome of tricuspid valve surgery in patients with CIEDs, particularly for the long-term results. With this study we aim to report the long-term result of tricuspid valve repair and replacement in patients with CIEDs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05774821
Study type	Observational
Source	Ospedale San Raffaele
Contact
Status	Completed
Phase
Start date	February 4, 2022
Completion date	February 27, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05434507` - Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter Annuloplasty System	N/A
Completed	`NCT03144024` - Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency	N/A
Enrolling by invitation	`NCT05825898` - Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
Completed	`NCT05836493` - Very Long-term (>15 Years) Results of Tricuspid Valve Repair.
Enrolling by invitation	`NCT06033274` - Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
Recruiting	`NCT05671640` - Feasibility Study of the DragonFly-T System for Severe Tricuspid Regurgitation	N/A
Recruiting	`NCT06027307` - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation	Phase 3
Terminated	`NCT04665583` - Prehab Prior to Undergoing Tricuspid Intervention
Recruiting	`NCT06307262` - European Registry of Transcatheter Repair for Tricuspid Regurgitation
Completed	`NCT02981953` - TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System	N/A
Recruiting	`NCT04433065` - TTVR Early Feasibility Study	N/A
Not yet recruiting	`NCT05556460` - Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation	N/A
Recruiting	`NCT05667519` - Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation (PLACE)	N/A
Recruiting	`NCT04653428` - German Registry for Transcatheter Tricuspid Valve Interventions
Recruiting	`NCT05179616` - Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair
Completed	`NCT02644616` - The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement	Phase 4
Recruiting	`NCT05328284` - PASCAL for Tricuspid Regurgitation - a European Registry
Completed	`NCT02675244` - Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery	N/A
Recruiting	`NCT05436028` - A Study to Evaluate the Safety and Performance of LuX-Valve Plus System for Tricuspid Replacement	N/A
Completed	`NCT01093001` - Tricuspid Regurgitation Study	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Surgical Treatment of Tricuspid Valve Regurgitation in Patients With Cardiac Implantable Electronic Devices: Long Term Results

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms